Whalesbook
UBS has initiated coverage on Shaily Engineering Plastics with a 'Buy' rating and a target price of Rs 4,000, suggesting a significant 60% upside potential. The brokerage identifies the company's healthcare division, driven by demand for injector devices for generic GLP-1 drugs, as the primary growth engine. UBS anticipates strong EPS growth and expects this segment to contribute substantially to revenue by FY28, driven by higher margins and capacity expansion.